CD4 and urinary bladder carcinoma: In addition, a recent study found that a cytolytic population of CD4+ T cells contributes significantly to anti-tumor immune activity in bladder cancer patients, and their infiltration into metastatic bladder tumors could predict clinical response to anti-PD-L1 therapy [39].